Features of the course of cardiovascular pathology and type 2 diabetes mellitus in patients with COVID-19
- Authors: Polozova E.I1, Skvortsov V.V2, Chegodaeva L.V1, Kurkina N.V1, Prokhorova T.A1, Al-Zakhar N.B.1, Nefedov N.S1
-
Affiliations:
- National Research Ogarev Mordovia State University
- Volgograd State Medical University
- Issue: Vol 32, No 1 (2021)
- Pages: 5-8
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114353
- DOI: https://doi.org/10.29296/25877305-2021-01-01
- ID: 114353
Cite item
Abstract
Full Text
About the authors
E. I Polozova
National Research Ogarev Mordovia State UniversityMD
V. V Skvortsov
Volgograd State Medical University
Email: vskvortsov1@ya.ru
MD
L. V Chegodaeva
National Research Ogarev Mordovia State UniversityCandidate of Medical Sciences
N. V Kurkina
National Research Ogarev Mordovia State UniversityCandidate of Medical Sciences
T. A Prokhorova
National Research Ogarev Mordovia State University
N. B.A Al-Zakhar
National Research Ogarev Mordovia State University
N. S Nefedov
National Research Ogarev Mordovia State University
References
- Беликина Д.В., Малышева Е.С., Петров А.В. и др. COVID-19 при сопутствующем сахарном диабете: особенности клинического течения, метаболизма, воспалительных и коагуляционных нарушений. Современные технологии в медицине. 2020; 12 (5): 6-18 [Belikina D.V., Malysheva E.S., Petrov A.V. et al. COVID-19 in patients with diabetes: clinical course, metabolic status, inflammation, and coagulation disorder. Sovremennye tehnologii vmedicine. 2020; 12 (5): 6-18 (in Russ.)]. https://doi.org/10.17691/stm2020.12.5.01
- Schiffrin E.L., Flack J.M., Ito S. et al. Hypertension and COVID-19. Am J. Hypertens. 2020; 33 (5): 373-4. doi: 10.1093/ajh/hpaa057
- Жмеренецкий К.В., Витько А.В., Петричко Т.А. и др. Сложные вопросы ведения пациентов с COVID-19, коморбидных по сердечно-сосудистым заболеваниям и сахарному диабету 2-го типа. Дальневосточный медицинский журнал. 2020; 2: 102-14 doi: 10.35177/1994-5191-20202-101-113
- Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020; 14 (3): 247-50. doi: 10.1016/j.dsx.2020.03.013
- Старшинова А.А., Кушнарева Е.А., Малкова А.М. и др. Новая коронавирусная инфекция: особенности клинического течения, возможности диагностики, лечения и профилактики инфекции у взрослых и детей. Вопросы современной педиатрии. 2020; 19 (2): 123-31 [Starshinova A.A., Kushnareva E.A., Malkova A.M. et al. New Coronaviral Infection: Features of Clinical Course, Capabilities of Diagnostics, Treatment and Prevention in Adults and Children. Current Pediatrics. 2020; 19 (2): 123-31 (in Russ.)]. https://doi.org/10.15690/vsp. v19i2.2105
- Ойноткинова О.Ш., Ларина В.Н., Зайратьянц О.В. Осложнения со стороны сердечно-сосудистой системы при COVID-19. Московская медицина. 2020; 3 (37): 80-9
- Kreutz R., Algharably E.A., Azizi M. et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020; 116 (10): 1688-99. doi: 10.1093/cvr/cvaa097
- Cole J.E., Park I., Ahern D.J. et al. Immune cell census in murine atherosclerosis: cytometry by time of fl ight illuminates vascular myeloid cell diversity. Cardiovasc Res. 2018; 114 (10): 1360-71. doi: 10.1093/cvr/cvy109
- Matysiak-Budnik T., Heyman M., Megraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003; 18 (Suppl. 1): 55-62. doi: 10.1046/j.1365-2036.18.s1.6.x
- Lin L., Jiang X., Zhang Z. at al. Gastrointestinal Symptoms of 95 Cases With SARS-CoV-2 Infection. Gut. 2020; 69 (6): 997-1001. DOI: 10.1136/ gutjnl-2020-321013
- Shim S., Jang H.S., Myung H.W. et al. Rebamipide ameliorates radiation-induced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017; 15 (329): 40-7. doi: 10.1016/j.taap.2017.05.012
- Liu K., Fang Y.Y., Deng Y. et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. (Engl). 2020; 133 (9): 1025-31. doi: 10.1097/CM9.0000000000000744
- Шестакова М.В., Викулова О.К., Исаков М.А. и др. Сахарный диабет и COVID-19: анализ клинических исходов по данным регистра сахарного диабета Российской Федерации. Проблемы эндокринологии. 2020; 66 (1): 35-46 [Shestakova M.V., Vikulova O.K., Isakov М.А. et al. Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the russian diabetes registry. Problems of Endocrinology. 2020; 66 (1): 35-46 (in Russ.)]. https://doi. org/10.14341/probl12458
- Wang A., Zhao W., Xu Z. et al. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract. 2020; 162: 108-18. doi: 10.1016/j.diabres.2020.108118
- Zhou F., Zhang Y., Chen J. et al. Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice. Eur J. Pharmacol. 2016; 791: 735-40. doi: 10.1016/j.ejphar.2016.10.016
- Kohio H.P., Adamson A.L. Glycolytic control of vacuolar-type ATPase activity: a mechanism to regulate influenza viral infection. Virology. 2013; 444 (1-2): 301-9. doi: 10.1016/j.virol.2013.06.026
- Gupta R., Ghosh A., Singh A.K. et al. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020; 14 (3): 211-2. doi: 10.1016/j.dsx.2020.03.002